- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00947154
Trial of Aripiprazole in Trichotillomania
Open Label Trial of Aripiprazole in Trichotillomania.
Study Overview
Detailed Description
The proposed study is an 8-week, open-label trial of aripiprazole. The study would enroll 10 patients diagnosed with TTM meeting DSM-IV criteria. Subjects would start at a dose of 5 mg, which can be reduced to 2 mg if initial dose is not tolerated. Dose will be increased by 5 mg every two weeks (or as tolerated, with a minimum increase of 2 mg) until a maximum target dose of 15 mg is reached at the beginning of week 5. Dosing would not be increased if a patient showed clinical improvement at a lower dose (defined as a 30% reduction in Massachusetts General Hairpulling Scale) or was intolerant of a further dose increase. Dose may not be increased after week 5; at any point it may be decreased because of intolerability. Modified dosing of aripiprazole will not automatically happen if a patient is taking fluoxetine or paroxetine, but awareness that increased aripiprazole levels are associated with P450 2D inhibition (and consequent tolerability of a given dose) may factor into clinical decisions to increase, maintain or decrease aripiprazole dosage.
Effectiveness: The primary measure of drug effect would be a change from baseline to endpoint in the Massachusetts General Hospital Hairpulling Scale (MGHHS) as well as the actual-pulling subscale (items 4,5,6; MGHHS-AP). Secondary measures would include the Clinical Global Impressions_Improvement scale (CGI-I), 17-item Hamilton Depression Scale (HAM-D) and the Hamilton Anxiety Scale (HAM-A).
Assessments: Primary efficacy measures will be assessed at baseline and at the end of weeks 2, 4, 6 and 8, or early termination. Week 2 and 6 follow-ups may occur over the telephone. Safety and tolerability will be assessed at each two-week interval. Secondary end-points will be assessed at baseline and weeks 4 and 8, or early termination.
Type and Number of Experimental Subjects and Controls: This study would enroll 10 patients at Stanford in a single-site study. Inclusion and exclusion criteria are described separately. Children will not be included in this proposed study, because the Investigator does not have clinical competency in child psychiatry and childhood Trichotillomania may be a different disorder than the condition seen in adults.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Eligible patients:
- Must be outpatients between the ages of 18 and 65 at the start of study
- May be male or female
- Have DSM-IV trichotillomania of at least 6 months duration
Allowed psychotropic medications are limited to:
- SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), SNRIs (duloxetine, venlafaxine) and mirtazapine, as long as the dosage has not changed for 4 weeks prior to study enrollment.
- Other allowed medications include non-hypnotic sleeping agents, specifically trazodone, diphenhydramine, hydoxyzine and ramelteon.
- If a patient is taking non-allowed psychotropic medications, he/she must be titrated off by the prescribing physician and be off of the medication for at least 2 weeks prior to trial enrollment.
We will not exclude patients meeting DSM-IV criteria for:
- body dysmorphic disorder;
- major depression;
- dysthymia;
- GAD, social phobia, panic disorder.
Exclusion Criteria:
We will exclude patients suffering from:
- organic mental disorders;
- psychotic mental disorders including delusional disorder, somatic type;
- mental retardation or developmental disabilities;
- substance or alcohol abuse;
- depressive disorders with current suicidal risk;
- factitious disorders;
- dissociative disorders;
- obsessive compulsive disorder;
- personality disorders sufficiently severe to interfere with cooperation with the study;
- bipolar I or II disorder.
- Patients taking psychotropic agents other than those specifically listed in item d above. If a patient is taking non-allowed psychotropic medications, he/she must be titrated off such medications by the prescribing physician and be off of the medication for 2 weeks prior to trial enrollment.
- Pregnant or nursing women.
- Patients with a known hypersensitivity or allergy to aripiprazole.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open-label aripiprazol
Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated.
Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase.
Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
|
aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated.
Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase.
Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mass General Hair Pulling Scale
Time Frame: Change from baseline to week 8
|
A brief, self-report instrument for assessing repetitive hairpulling.
Seven individual items, rated for severity from 0 to 4, assess frequency and intensity of urges to pull, ability to control the urges, frequency of pulling, attempts to resist pulling, success in resisting, and associated distress.
Statistical analyses indicate that the seven items form a homogenous scale for the measurement of severity in trichotillomania.
Higher scores indicate greater severity of hair pulling.
Total score can range from 0 to 28.
|
Change from baseline to week 8
|
Mass General Hair Pulling Scale, Actual Pulling Subscale
Time Frame: change from baseline to end of week 8
|
Sum of scores for items 4, 5 and 6 from the Mass General Hair Pulling Scale (Frequency of Pulling, Attempts to Resist Pulling, Control Over Hair Pulling).
Score can range from 0 to 12; higher scores indicate more severe hair pulling.
|
change from baseline to end of week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CGI-I Score of 1 or 2 (Very Much or Much Improved)
Time Frame: At week 8
|
CGI = Clinical Global Improvement 7-item scale, from very much worse to very much better.
|
At week 8
|
Clinical Global Impressions Improvement (CGI-I)
Time Frame: At week 8
|
The CGI-I is a clinician rated scale ranging from 0 (not assessed) to 7 (very much worse), with intermediate scores of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse).
The clinician is rating the overall change in the patient's clinical condition.
|
At week 8
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Disruptive, Impulse Control, and Conduct Disorders
- Trichotillomania
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
Other Study ID Numbers
- SU-07172009-3320
- eProtocol #15291 (Other Grant/Funding Number: NIMH T32 training grant)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trichotillomania
-
Johns Hopkins UniversityRecruitingTrichotillomania | Trichotillomania (Hair-Pulling Disorder) | Hair PullingUnited States
-
University of ChicagoNot yet recruitingTrichotillomania (Hair-Pulling Disorder) | DermatillomaniaUnited States
-
University of ChicagoCompletedTrichotillomania (Hair-Pulling Disorder) | DermatillomaniaUnited States
-
University of ChicagoRecruitingTrichotillomania (Hair-Pulling Disorder) | Skin-PickingUnited States
-
American UniversityCompletedTrichotillomania (Hair-Pulling Disorder) | Skin-PickingUnited States
-
Yale UniversityNeurocrine BiosciencesRecruitingTrichotillomania (Hair-Pulling Disorder)United States
-
HabitAware Inc.National Institute of Mental Health (NIMH); Marquette UniversityCompletedTrichotillomaniaUnited States
-
University of Wisconsin, MilwaukeeCompleted
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedTrichotillomaniaUnited States
-
University of Sao PauloCompleted
Clinical Trials on aripiprazole
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityCompleted
-
Otsuka Beijing Research InstituteCompleted
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
University of California, Los AngelesAlkermes, Inc.TerminatedSchizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive TypeUnited States
-
Otsuka Pharmaceutical Co., Ltd.CompletedMajor Depressive DisorderJapan
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Otsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaJapan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Alkermes, Inc.CompletedSchizophreniaUnited States
-
Alkermes, Inc.CompletedSchizophreniaUnited States